Literature DB >> 14514600

Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up.

Qing Qiao1, Pekka Jousilahti, Johan Eriksson, Jaakko Tuomilehto.   

Abstract

OBJECTIVE: To evaluate the relationship of impaired glucose tolerance (IGT) at baseline to coronary heart disease (CHD) incidence, and cardiovascular disease (CVD) and total mortality at follow-up, and to analyze whether the relationship is independent of the subsequent development of diabetes during follow-up. RESEARCH DESIGN AND METHODS: A baseline screening survey for diabetes was performed in 1987 using a 2-h 75-g oral glucose tolerance test. A total of 1234 men and 1386 women aged 45-64 years, who were free of diabetes at baseline, were followed up for 10 years. During the follow-up, 153 subjects had an incident CHD event, 224 died, and 100 deaths were due to cardiovascular causes. Multivariate adjusted (adjusted for age, sex, waist-to-hip ratio, systolic blood pressure, cholesterol, HDL cholesterol, and smoking) hazard ratio (HR) was estimated using Cox regression analysis.
RESULTS: In subjects who had IGT at baseline and who did not progress to diabetes during the follow-up, the multivariate adjusted HR (95% CI) was 1.49 (0.95-2.34) for CHD incidence, 2.34 (1.42-3.85) for CVD mortality, and 1.65 (1.13-2.40) for all-cause mortality.
CONCLUSIONS: Baseline IGT was an independent risk predictor for cardiovascular morbidity and mortality and for total mortality, which was not confounded by the subsequent development of overt diabetes.

Entities:  

Mesh:

Year:  2003        PMID: 14514600     DOI: 10.2337/diacare.26.10.2910

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  21 in total

1.  Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes?

Authors:  Leigh Perreault; Bryan C Bergman; Mary C Playdon; Chiara Dalla Man; Claudio Cobelli; Robert H Eckel
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-03       Impact factor: 4.310

Review 2.  Predictors of cardiovascular risk in women.

Authors:  Tamer Sallam; Karol E Watson
Journal:  Womens Health (Lond)       Date:  2013-09

3.  Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study.

Authors:  H Hämäläinen; T Rönnemaa; A Virtanen; J Lindström; J G Eriksson; T T Valle; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Rastas; S Aunola; M Uusitupa; J Tuomilehto
Journal:  Diabetologia       Date:  2005-10-05       Impact factor: 10.122

4.  How can we identify candidates at highest risk--to screen or not to screen?

Authors:  N C Barengo; J O Tuomilehto
Journal:  Herz       Date:  2016-05       Impact factor: 1.443

5.  TRAF4 functions as an intermediate of GITR-induced NF-kappaB activation.

Authors:  E M Esparza; R H Arch
Journal:  Cell Mol Life Sci       Date:  2004-12       Impact factor: 9.261

Review 6.  Differential effects of antihypertensive drugs on new-onset diabetes?

Authors:  William J Elliott
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

7.  Cardiovascular disease risk in people with spinal cord injury: is there a possible association between reduced lung function and increased risk of diabetes and hypertension?

Authors:  B F Köseoğlu; V B Safer; Ö Öken; S Akselim
Journal:  Spinal Cord       Date:  2016-07-05       Impact factor: 2.772

8.  Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China.

Authors:  Chang-Yu Pan; Harald Landen
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

9.  Cross-sectional and prospective study of the association between lung function and prediabetes.

Authors:  Takashi Yamane; Akihito Yokoyama; Yoshihiro Kitahara; Shintaro Miyamoto; Yoshinori Haruta; Noboru Hattori; Kiminori Yamane; Hitoshi Hara; Nobuoki Kohno
Journal:  BMJ Open       Date:  2013-02-20       Impact factor: 2.692

Review 10.  Nonpharmacologic therapy and exercise in the prevention of type 2 diabetes.

Authors:  Jaakko Tuomilehto
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.